Method for treating cancer by administering MAGE-derived peptides

• US 6,488,932 B1
• Filed: 12/12/1995
• Issued: 12/03/2002
• Est. Priority Date: 08/31/1992
• Status: Expired due to Term

• Current Assignee: Ludwig Institute for Cancer Research, Ltd.
• Original Assignee: Ludwig Institute for Cancer Research, Ltd.
• Inventors: De Plaen, Etienne, Traversari, Catia, Lurquin, Christophe, Boon, Thierry, van der Bruggen, Pierre
• Primary Examiner(s): Chan, Christina Y.
• Assistant Examiner(s): SCHWADRON, RONALD B
• Application Number:
  US08/571,263
• Time in Patent Office: 2,548 Days
• Field of Search: 424/185.1, 424/277.1, 424/193.1, 530/328, 530/300, 530/335, 530/402
• US Class Current: 424/185.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 16/30 from tumour cells

Abstract

The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Claims

1. A method for treating a patient afflicted with a tumor, neoplasm or cancer which expresses a tumor rejection antigen precursor and presents HLA-A1 molecules on cell surfaces of said tumor, neoplasm or cancer, comprising administering to said patient an amount of a nonapeptide, the amino acid sequence of which is set forth at SEQ ID NO:

17, sufficient to form complexes between said nonapeptide and said HLA-A1 molecules and induce lysis of cells of said tumor, neoplasm, or cancer which present complexes of said nonapeptide and said HLA-A1 molecule by cytolytic T cells of said patient.

2. The method of claim 1, wherein said patient expresses tumor rejection antigen precursor MAGE-3.

3. The method of claim 1, wherein said nonapeptide is administered via direct injection, time release administration, or via coupling to a tumor specific antibody.

4. The method of claim 1, wherein said cancer is melanoma.